419 related articles for article (PubMed ID: 31986961)
1. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Virtual Screening towards the Discovery of Novel ULK1 Inhibitors with Anti-HCC Activities.
Gao Y; Zhou Z; Zhang T; Xue S; Li K; Jiang J
Molecules; 2022 Apr; 27(9):. PubMed ID: 35565977
[TBL] [Abstract][Full Text] [Related]
3. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
[TBL] [Abstract][Full Text] [Related]
4. Isoginkgetin, a potential CDK6 inhibitor, suppresses
Yao J; Tang S; Shi C; Lin Y; Ge L; Chen Q; Ou B; Liu D; Miao Y; Xie Q; Tang X; Fei J; Yang G; Tian J; Zeng X
Autophagy; 2023 Apr; 19(4):1221-1238. PubMed ID: 36048765
[TBL] [Abstract][Full Text] [Related]
5. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
7. Autophagic protein ULK1 regulates FOXM1 signalling in human hepatoma cells.
Rajak S; Raza S; Tewari A; Yadav S; Ghosh S; Yen PM; Sinha RA
Biochem Biophys Res Commun; 2020 Nov; 532(4):570-575. PubMed ID: 32900486
[TBL] [Abstract][Full Text] [Related]
8. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
Wang X; Wu F; Li G; Zhang N; Song X; Zheng Y; Gong C; Han B; He G
Acta Biomater; 2018 Jul; 74():414-429. PubMed ID: 29787814
[TBL] [Abstract][Full Text] [Related]
9. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
10. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
[No Abstract] [Full Text] [Related]
11. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
12. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
Chen S; Du Y; Xu B; Li Q; Yang L; Jiang Z; Zeng Z; Chen L
Oncogene; 2021 May; 40(19):3378-3393. PubMed ID: 33875785
[TBL] [Abstract][Full Text] [Related]
13. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.
Zhou B; Lu Q; Liu J; Fan L; Wang Y; Wei W; Wang H; Sun G
Int J Biol Sci; 2019; 15(9):1905-1920. PubMed ID: 31523192
[TBL] [Abstract][Full Text] [Related]
14. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
15. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
Wang D; Yang J
Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma
Xiao Q; Liu H; Wang HS; Cao MT; Meng XJ; Xiang YL; Zhang YQ; Shu F; Zhang QG; Shan H; Jiang GM
Theranostics; 2020; 10(22):10245-10261. PubMed ID: 32929346
[TBL] [Abstract][Full Text] [Related]
17. Combination of ULK1 and LC3B improve prognosis assessment of hepatocellular carcinoma.
Wu DH; Wang TT; Ruan DY; Li X; Chen ZH; Wen JY; Lin Q; Ma XK; Wu XY; Jia CC
Biomed Pharmacother; 2018 Jan; 97():195-202. PubMed ID: 29091866
[TBL] [Abstract][Full Text] [Related]
18. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
19. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
20. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]